Immune checkpoint therapy—current perspectives and future directions
P Sharma, S Goswami, D Raychaudhuri, BA Siddiqui… - Cell, 2023 - cell.com
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …
patients and conferred durable clinical benefits, including cure in a subset of patients …
CD4+ T cells in cancer
Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
DR Wang, XL Wu, YL Sun - Signal transduction and targeted therapy, 2022 - nature.com
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …
malignant cells but also an altered immune response. The inhibition and reprogramming of …
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade
Immune-checkpoint blockade (ICB) therapies represent a paradigm shift in the treatment of
human cancers; however, it remains incompletely understood how tumor-reactive T cells …
human cancers; however, it remains incompletely understood how tumor-reactive T cells …
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
JM Llovet, R Pinyol, RK Kelley, A El-Khoueiry… - Nature cancer, 2022 - nature.com
Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …
The poor outcome associated with HCC is dramatically changing due to the advent of …
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
AJ Korman, SC Garrett-Thomson… - Nature Reviews Drug …, 2022 - nature.com
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …
discussion and experimentation for over a hundred years. Several successful cancer …
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
L Kraehenbuehl, CH Weng, S Eghbali… - Nature reviews Clinical …, 2022 - nature.com
The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the …
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the …
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer
Anti-PD-1 treatment has shown unprecedented clinical success in the treatment of non-small-
cell lung cancer (NSCLC), but the underlying mechanisms remain incompletely understood …
cell lung cancer (NSCLC), but the underlying mechanisms remain incompletely understood …
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
A VanderWalde, SL Bellasea, KL Kendra… - Nature medicine, 2023 - nature.com
In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with
continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic …
continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic …